Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272524 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL12003052 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL4329020 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL13437816 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL7804687 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL13403865 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL4065444 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL12003035 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B | |
| SCHEMBL13403872 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B | |
| SCHEMBL272221 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906878-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906878-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120251440-A1 | METHODS OF MYOCARDIAL PERFUSION IMAGING | GILEAD SCIENCES, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251440-A1 | METHODS OF MYOCARDIAL PERFUSION IMAGING | GILEAD SCIENCES, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133879-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080267861-A1 | Myocardial Perfusion Imaging | CV THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080267861-A1 | Myocardial Perfusion Imaging | CV THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | CV THERAPEUTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008028140-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070299089-A1 | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia | CV THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299089-A1 | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia | CV THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299089-A1 | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885 |
| US-20080267861-A1 | Myocardial Perfusion Imaging | TNNI3, FLT4, FABP3 | ADORA2A 100/4885ADORA2B 92/4885 |
| US-20120251440-A1 | METHODS OF MYOCARDIAL PERFUSION IMAGING | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885 |
| US-20080213165-A1 | Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885 |
| US-20080170990-A1 | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease | ADORA2A, ADORA3, ADRB3 | ADORA2A 1/4885ADORA2B 5/4885 |
| US-20090081120-A1 | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods | ADORA2A, FABP3, ADORA3 | ADORA2A 1/4885ADORA2B 9/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.